Epicrispr Biotechnologies has raised another $90 million to accelerate development of a first-of-its-kind treatment for a rare genetic muscle disorder. With EPI-321, Epicrispr is using this strategy to silence the genetic driver of facioscapulohumeral muscular dystrophy, or FSHD, a progressive neuromuscular condition. In FSHD, for instance, the overexpression of a gene called DUX4 causes muscle atrophy and degeneration. Rather than cut into that gene, EPI-321 binds to a specific area of DUX4 and makes a chemical modification that suppresses production of its encoded protein. Early clinical data have shown the potential to boost muscle volume and impact biological markers associated with DUX4 suppression.